Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 18/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | PLD2 | O14939 | 1/20 | 0.64 |
| ▸ | KDM1A | O60341 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | C5 | P01031 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3974968 | 0.99 | ESR1 (0.64) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL7092816 | 0.88 | ESR1 (0.63) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL3691182 | 0.87 | ESR1 (0.70) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL31247338 | 0.86 | ESR1 (0.70) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL5595806 | 0.85 | ESR1 (0.57) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL5595801 | 0.84 | ESR1 (0.59) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL8577743 | 0.84 | ESR1 (0.44) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL8090140 | 0.84 | ESR1 (0.78) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL8866853 | 0.84 | ENPP3 (0.56) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL7942841 | 0.81 | ESR1 (0.52) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
| EP-2446276-B9 | METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-05-04 | — | — | EP | disclosed |
| EP-2446276-B1 | METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2014-08-20 | — | — | EP | disclosed |
| EP-2448562-B1 | RALOXIFENE COMPOSITION | SYNTHON BV (NL) | 2013-11-06 | — | — | EP | disclosed |
| EP-2242483-B1 | RALOXIFENE COMPOSITION | SYNTHON BV (NL) | 2013-02-20 | — | — | EP | disclosed |
| EP-2448562-A2 | RALOXIFENE COMPOSITION | Synthon B.V. (NL) | 2012-05-09 | — | — | EP | disclosed |
| EP-2446276-A1 | METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2012-05-02 | — | — | EP | disclosed |
| WO-2011000581-A2 | RALOXIFENE COMPOSITION | SYNTHON B.V. (NL) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010149941-A1 | METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-12-29 | — | — | WO | disclosed |
| EP-2242483-A1 | RALOXIFENE COMPOSITION | Synthon B.V. (NL) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009080364-A1 | RALOXIFENE COMPOSITION | SYNTHON B.V. (NL) | 2009-07-02 | — | — | WO | disclosed |
| EP-0703231-B1 | 2-(4-Hydroxyphenyl)benzothiophene compounds, compositions and methods for alleviating the symptoms of post-menopause syndrome | LILLY CO ELI (US) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | ESR1 1749/4885ESR2 1225/4885MEN1 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.